Enriched Tear Film (ETF™) Gene Therapy

Harnessing the body’s natural mechanism to heal the cornea, Oyster Point has pioneered a novel approach to potentially treat diseases of the ocular surface. ETF™ Gene Therapy is an adeno-associated virus (AAV)-based approach where, via intralacrimal gland injection, the lacrimal gland cells are provided a genetic message that may change cell behavior and function on the ocular surface. The genetic message may direct the production of selected antibodies, hormones, peptides, enzymes or cytokines that are secreted into the lacrimal fluid and ultimately combine with the tear film on the ocular surface. Our initial gene therapy targets are focused on chronic diseases of the ocular surface using selected, naturally occurring human proteins, peptides, or enzymes.

In diseases of the ocular surface where there is inadequate tear film production, or where increased amounts of selected gene product are needed, secretion of the selected gene product may be modulated with administration of OC-01 (varenicline) nasal spray, which has been shown in preclinical and clinical models to increase tear film production.

injection
Injection
Protein Production in the Lacrimal Gland
Protein Production in the Lacrimal Gland
Cholinergic Stimulation of Tear Production
Cholinergic Stimulation of Tear Production
The intra-lacrimal gland injection of AAV is intended to be administered as an in-office procedure using topical anesthesia, if approved for use by the US Food and Drug Administration (FDA).

OC-101 (AAV-NGF)

Adeno-associated virus (AAV) vectors are nonreplicating DNA delivery vehicles that are currently not known to cause disease. OC-101 (AAV-NGF) is Oyster Point’s investigational gene therapy in development as part of Oyster Point’s proprietary development approach of utilizing Enriched Tear Film (ETF™) Gene Therapy to treat select ocular surface diseases. OC-101 is an AAV containing the nerve growth factor (NGF) gene. NGF is a naturally occurring protein secreted by cells on the surface of the cornea and involved in the differentiation and maintenance of neurons that has been shown to heal the corneal epithelium and improve corneal sensitivity1. Once administered to the lacrimal gland, OC-101 (AAV-NGF) has been shown in preclinical studies to harness the body’s protein-producing machinery to produce NGF, which was then secreted into the tear film and onto the ocular surface.

OC-101 (AAV-NGF) is an investigational gene therapy that has not been tested in humans and has not been approved for any use in any country. The safety and efficacy of OC-101 (AAV-NGF) have not been established.

Enriched Tear Film (ETF™) Gene Therapy in Action

See the workings of Oyster Point’s novel approach to treating ocular surface diseases.

Enriched Tear Film (ETF) Gene Therapy In Action

See the workings of Oyster Point’s novel approach to treating ocular surface diseases.

Pipeline
Explore Oyster Point’s complete research and development program.
Our Focus
Learn about our dedication to therapies for the ocular surface.
References
1 Mastropasqua, L., Lanzini, M., Dua, H. S., D’Uffizi, A., Di Nicola, M., Calienno, R., … & Nubile, M. (2020). In vivo evaluation of corneal nerves and epithelial healing after treatment with recombinant nerve growth factor for neurotrophic keratopathy. American Journal Of Ophthalmology, 217, 278-286.